Review | Latest updates on quadruplet therapy for newly diagnosed MM

This article focuses on the addition of mAbs to standard triplet regimens as frontline treatment for newly diagnosed MM (NDMM), and their latest clinical updates from the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) 2020 meetings.